2023
Age-related, multivariate associations between white matter microstructure and behavioral performance in three executive function domains
Anderson J, Calhoun V, Pearlson G, Hawkins K, Stevens M. Age-related, multivariate associations between white matter microstructure and behavioral performance in three executive function domains. Developmental Cognitive Neuroscience 2023, 64: 101318. PMID: 37875033, PMCID: PMC10618425, DOI: 10.1016/j.dcn.2023.101318.Peer-Reviewed Original ResearchConceptsExecutive function domainsResponse inhibitionWhite matter microstructureLower response inhibitionStructure-cognition relationshipsEF abilitiesBehavioral performanceCognitive imbalanceNeurocognitive testsFunction domainTest performanceYoung adulthoodFractional anisotropyBrain changesAge 12Young adultsSS performanceWhite matter FA valuesGreater relianceWhite matter changesWhite matter microstructural differencesSubjects ages 12White matter skeletonIndependent componentsMultivariate associations
2020
Neuropsychiatric symptoms and cognitive abilities over the initial quinquennium of Parkinson disease
Weintraub D, Caspell‐Garcia C, Simuni T, Cho HR, Coffey CS, Aarsland D, Alcalay RN, Barrett MJ, Chahine LM, Eberling J, Espay AJ, Hamilton J, Hawkins KA, Leverenz J, Litvan I, Richard I, Rosenthal LS, Siderowf A, York M, Initiative P. Neuropsychiatric symptoms and cognitive abilities over the initial quinquennium of Parkinson disease. Annals Of Clinical And Translational Neurology 2020, 7: 449-461. PMID: 32285645, PMCID: PMC7187707, DOI: 10.1002/acn3.51022.Peer-Reviewed Original ResearchConceptsParkinson's disease participantsNeuropsychiatric symptomsParkinson's diseaseHealthy controlsCognitive impairmentMedication useYear 5Anticholinergic medication useCross-sectional prevalenceParkinson's disease patientsHypnotic useDisease patientsNeuropsychiatric featuresDisease onsetAnnual visitsSymptomsDisorder subtypesAbsolute prevalenceDiseaseTime pointsPrevalenceBaselineImpairmentParticipantsOnset
2018
Cognition among individuals along a spectrum of increased risk for Parkinson’s disease
Chahine LM, Urbe L, Caspell-Garcia C, Aarsland D, Alcalay R, Barone P, Burn D, Espay AJ, Hamilton JL, Hawkins KA, Lasch S, Leverenz JB, Litvan I, Richard I, Siderowf A, Coffey CS, Simuni T, Weintraub D, Initiative T. Cognition among individuals along a spectrum of increased risk for Parkinson’s disease. PLOS ONE 2018, 13: e0201964. PMID: 30125297, PMCID: PMC6101368, DOI: 10.1371/journal.pone.0201964.Peer-Reviewed Original ResearchConceptsParkinson's diseaseIdiopathic REM sleep behavior disorderParkinson's Progression Markers Initiative (PPMI) studyDe novo Parkinson's diseaseREM sleep behavior disorderDopamine transporterNon-motor symptomsNovo Parkinson's diseaseSleep behavior disorderNon-motor featuresSymbol Digit Modalities TestBaseline neuropsychological performanceMontreal Cognitive AssessmentFuture neurodegenerationLewy bodiesInclusion criteriaSpectrum of riskMutation carriersInitiative studyCohortBehavior disorderCognitive functionCognitive test scoresModalities TestNeuropsychological performanceRelationship between fMRI response during a nonverbal memory task and marijuana use in college students
Dager AD, Tice MR, Book GA, Tennen H, Raskin SA, Austad CS, Wood RM, Fallahi CR, Hawkins KA, Pearlson GD. Relationship between fMRI response during a nonverbal memory task and marijuana use in college students. Drug And Alcohol Dependence 2018, 188: 71-78. PMID: 29754029, PMCID: PMC6756147, DOI: 10.1016/j.drugalcdep.2018.03.025.Peer-Reviewed Original ResearchConceptsInferior frontal gyrusMJ usersFMRI responsesCollege studentsMemory taskMJ useFunctional magnetic resonance imaging (fMRI) responsesNonverbal memory tasksLower fMRI responseRecognition memoryNeural correlatesMagnetic resonance imaging responseFrontal gyrusVisual encodingRecognition taskOccupational functioningAge 18Memory dysfunctionMarijuana useAcademic performanceLeft hippocampusHippocampal dysfunctionGroup differencesRight hippocampusTaskLongitudinal Effects of Alcohol Consumption on the Hippocampus and Parahippocampus in College Students
Meda SA, Hawkins KA, Dager AD, Tennen H, Khadka S, Austad CS, Wood RM, Raskin S, Fallahi CR, Pearlson GD. Longitudinal Effects of Alcohol Consumption on the Hippocampus and Parahippocampus in College Students. Biological Psychiatry Cognitive Neuroscience And Neuroimaging 2018, 3: 610-617. PMID: 29680476, PMCID: PMC6062479, DOI: 10.1016/j.bpsc.2018.02.006.Peer-Reviewed Original ResearchConceptsAlcohol consumptionAlcohol use indicesHippocampal volume declineBrain magnetic resonanceLongitudinal effectsMemory scoresCalifornia Verbal Learning Test-IIAlcohol-induced memory blackoutsPara-hippocampusHippocampal volumeMemory blackoutsLongitudinal brainVolume declineDrinking indicesLongitudinal pipelinePoorer memory performancePoorer memory scoresHippocampusTest IICross-sectional literatureDrinking-related measuresBrainAlcohol researchMagnetic resonanceScores
2017
Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson disease
Caspell-Garcia C, Simuni T, Tosun-Turgut D, Wu IW, Zhang Y, Nalls M, Singleton A, Shaw LA, Kang JH, Trojanowski JQ, Siderowf A, Coffey C, Lasch S, Aarsland D, Burn D, Chahine LM, Espay AJ, Foster ED, Hawkins KA, Litvan I, Richard I, Weintraub D, Initiative T. Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson disease. PLOS ONE 2017, 12: e0175674. PMID: 28520803, PMCID: PMC5435130, DOI: 10.1371/journal.pone.0175674.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAmyloid beta-PeptidesBiomarkersBrain-Derived Neurotrophic FactorCatechol O-MethyltransferaseCognitive DysfunctionDiffusion Tensor ImagingDopamine Plasma Membrane Transport ProteinsFemaleHumansMagnetic Resonance ImagingMaleMiddle AgedParkinson DiseasePolymorphism, Single NucleotideTau ProteinsTomography, Emission-Computed, Single-PhotonConceptsParkinson's diseaseCognitive impairmentDe novo Parkinson's diseaseDopamine transporter single-photon emissionLongitudinal mixed-effects modelsNovo Parkinson's diseaseYears of diseaseIdiopathic Parkinson's diseaseMovement Disorders CenterSingle nucleotide polymorphismsStructural magnetic resonance imagingClinical trial designLongitudinal structural MRIMagnetic resonance imagingSingle photon emissionDevelopment of treatmentsDiffusion tensor imagingBiomarker predictorsPlaque pathologyAmyloid pathologyDopamine deficiencyDopaminergic deficitUnivariate analysisBiomarker changesDisorders Center
2015
Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease
Weintraub D, Simuni T, Caspell‐Garcia C, Coffey C, Lasch S, Siderowf A, Aarsland D, Barone P, Burn D, Chahine M, Eberling J, Espay AJ, Foster ED, Leverenz JB, Litvan I, Richard I, Troyer MD, Hawkins KA, Initiative T. Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease. Movement Disorders 2015, 30: 919-927. PMID: 25737166, PMCID: PMC4855523, DOI: 10.1002/mds.26170.Peer-Reviewed Original ResearchConceptsParkinson's Progression Markers InitiativeNeuropsychiatric symptomsPD patientsHealthy controlsProgression Markers InitiativeParkinson's diseaseCognitive impairmentUntreated PD patientsDopamine replacement therapySignificant depressive symptomsGroup differencesSymptoms of depressionQuality of lifeMild cognitive impairmentUntreated patientsDisease courseReplacement therapyICD symptomsControl disordersDepressive symptomsGeneral populationPatientsMeeting criteriaMulti-site studyBiological predictors
2014
Genetic association of impulsivity in young adults: a multivariate study
Khadka S, Narayanan B, Meda SA, Gelernter J, Han S, Sawyer B, Aslanzadeh F, Stevens MC, Hawkins KA, Anticevic A, Potenza MN, Pearlson GD. Genetic association of impulsivity in young adults: a multivariate study. Translational Psychiatry 2014, 4: e451-e451. PMID: 25268255, PMCID: PMC4199418, DOI: 10.1038/tp.2014.95.Peer-Reviewed Original Research
2013
Transcranial Magnetic Stimulation of Wernicke’s and Right Homologous Sites to Curtail “Voices”: A Randomized Trial
Hoffman RE, Wu K, Pittman B, Cahill JD, Hawkins KA, Fernandez T, Hannestad J. Transcranial Magnetic Stimulation of Wernicke’s and Right Homologous Sites to Curtail “Voices”: A Randomized Trial. Biological Psychiatry 2013, 73: 1008-1014. PMID: 23485015, PMCID: PMC3641174, DOI: 10.1016/j.biopsych.2013.01.016.Peer-Reviewed Original Research
2012
Glycine treatment of the risk syndrome for psychosis: Report of two pilot studies
Woods SW, Walsh BC, Hawkins KA, Miller TJ, Saksa JR, D'Souza DC, Pearlson GD, Javitt DC, McGlashan TH, Krystal JH. Glycine treatment of the risk syndrome for psychosis: Report of two pilot studies. European Neuropsychopharmacology 2012, 23: 931-940. PMID: 23089076, PMCID: PMC4028140, DOI: 10.1016/j.euroneuro.2012.09.008.Peer-Reviewed Original ResearchConceptsPilot studyRisk syndromeSyndrome patientsNegative symptomsShort-term pilot studyEffect sizeAdjunctive antipsychotic medicationOpen-label studyPatients meeting criteriaNMDA receptor functionDurability of effectPsychosis risk symptomsGlycine site agonistsGroup effect sizesWeeks of evaluationAntipsychotic medicationSyndrome subjectsPromising effect sizesTreatment needsLarge effect sizesMeeting criteriaCognitive impairmentReduced symptomsReceptor functionSymptomsDefault mode network activity and white matter integrity in healthy middle-aged ApoE4 carriers
Patel KT, Stevens MC, Pearlson GD, Winkler AM, Hawkins KA, Skudlarski P, Bauer LO. Default mode network activity and white matter integrity in healthy middle-aged ApoE4 carriers. Brain Imaging And Behavior 2012, 7: 60-67. PMID: 23011382, DOI: 10.1007/s11682-012-9187-y.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnxietyApolipoprotein E4BrainData Interpretation, StatisticalDepressionDiffusion Tensor ImagingDNAFemaleGenotypeHeterozygoteHumansImage Processing, Computer-AssistedIntelligence TestsMagnetic Resonance ImagingMaleMiddle AgedNerve NetNeuropsychological TestsPrincipal Component AnalysisSmokingWechsler ScalesConceptsAPOE4 carriersMagnetic resonance imagingAlzheimer's diseaseFractional anisotropyFunctional MRI abnormalitiesUnderlying neuropathologic changesWhite matter fractional anisotropyWhite matter changesDefault mode network connectivityDefault mode network activityGenetic risk factorsMode network connectivityMiddle-aged adultsWhite matter integrityMRI abnormalitiesNeuropathologic changesRisk factorsApolipoprotein EMatter changesCognitive declineResonance imagingOlder ageFunctional connectivityGenetic riskDMN regions
2010
Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study.
Woods SW, Morgenstern H, Saksa JR, Walsh BC, Sullivan MC, Money R, Hawkins KA, Gueorguieva RV, Glazer WM. Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study. The Journal Of Clinical Psychiatry 2010, 71: 463-74. PMID: 20156410, PMCID: PMC3109728, DOI: 10.4088/jcp.07m03890yel.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAmbulatory CareAntipsychotic AgentsCohort StudiesCommunity Mental Health CentersConnecticutDiagnostic and Statistical Manual of Mental DisordersDyskinesia, Drug-InducedFemaleHumansIncidenceLongitudinal StudiesMaleMental DisordersMiddle AgedPrevalenceProspective StudiesPsychiatric Status Rating ScalesRisk FactorsSeverity of Illness IndexConceptsProspective cohort studyConventional antipsychoticsTardive dyskinesiaAtypical antipsychoticsCohort studyPrevious prospective cohort studyCommunity mental health centerConventional antipsychotic medicationsMental health centersAntipsychotic medicationHealth centersBaseline evaluationAntipsychoticsNew diagnosisDyskinesiaClinical practicePsychiatric outpatientsRecent exposureIncidencePrevious visitPrevious studiesPrevalenceSubjectsCurrent studyMost previous studies
2007
Aripiprazole in the treatment of the psychosis prodrome
Woods SW, Tully EM, Walsh BC, Hawkins KA, Callahan JL, Cohen SJ, Mathalon DH, Miller TJ, McGlashan TH. Aripiprazole in the treatment of the psychosis prodrome. The British Journal Of Psychiatry. Supplement 2007, 191: s96-s101. PMID: 18055946, DOI: 10.1192/bjp.191.51.s96.Peer-Reviewed Original ResearchConceptsPsychosis prodromeMixed-effects repeated-measures analysisShort-term efficacySymptom total scoreSingle-site trialRepeated-measures analysisAripiprazole treatmentAdverse eventsFinal visitSafety profilePromising efficacyProdromal phasePsychotic disordersScale scoreBaseline levelsWeight gainFirst weekProdromeTotal scoreAripiprazoleTreatmentNeuropsychological measuresPreliminary evidenceWeeksEfficacyProbing the Pathophysiology of Auditory/Verbal Hallucinations by Combining Functional Magnetic Resonance Imaging and Transcranial Magnetic Stimulation
Hoffman RE, Hampson M, Wu K, Anderson AW, Gore JC, Buchanan RJ, Constable RT, Hawkins KA, Sahay N, Krystal JH. Probing the Pathophysiology of Auditory/Verbal Hallucinations by Combining Functional Magnetic Resonance Imaging and Transcranial Magnetic Stimulation. Cerebral Cortex 2007, 17: 2733-2743. PMID: 17298962, PMCID: PMC2634833, DOI: 10.1093/cercor/bhl183.Peer-Reviewed Original ResearchConceptsRepetitive transcranial magnetic stimulationTranscranial magnetic stimulationFunctional magnetic resonance imagingMagnetic resonance imagingMagnetic stimulationSham stimulationTemporoparietal repetitive transcranial magnetic stimulationAuditory/verbal hallucinationsResonance imagingWernicke's areaVerbal hallucinationsBOLD signal time coursesBroca's areaSchizophrenia spectrum disordersGreater rateInferior frontal regionsPatientsTemporoparietal areasSignal time courseCortical sitesPathophysiologySupramarginal gyrusHallucinationsRight homologueStimulation
2005
Temporoparietal Transcranial Magnetic Stimulation for Auditory Hallucinations: Safety, Efficacy and Moderators in a Fifty Patient Sample
Hoffman RE, Gueorguieva R, Hawkins KA, Varanko M, Boutros NN, Wu YT, Carroll K, Krystal JH. Temporoparietal Transcranial Magnetic Stimulation for Auditory Hallucinations: Safety, Efficacy and Moderators in a Fifty Patient Sample. Biological Psychiatry 2005, 58: 97-104. PMID: 15936729, DOI: 10.1016/j.biopsych.2005.03.041.Peer-Reviewed Original ResearchConceptsRepetitive transcranial magnetic stimulationTranscranial magnetic stimulationAuditory hallucinationsSham stimulationMagnetic stimulationTemporoparietal repetitive transcranial magnetic stimulationClinical Global Impression ScaleGlobal Impression ScaleRight-handed patientsMotor thresholdImpression ScaleRTMS effectsNew patientsNeurocognitive impairmentHallucination frequencySchizoaffective disorderPatient samplesSignificant distressPatientsChange scoresHallucinationsPreliminary reportStimulationNeurobiological factorsIntervention
2004
Factorial structure of the Scale of Prodromal Symptoms
Hawkins KA, McGlashan TH, Quinlan D, Miller TJ, Perkins DO, Zipursky RB, Addington J, Woods SW. Factorial structure of the Scale of Prodromal Symptoms. Schizophrenia Research 2004, 68: 339-347. PMID: 15099615, DOI: 10.1016/s0920-9964(03)00053-7.Peer-Reviewed Original ResearchNeuropsychological status of subjects at high risk for a first episode of psychosis
Hawkins KA, Addington J, Keefe RS, Christensen B, Perkins DO, Zipurksy R, Woods SW, Miller TJ, Marquez E, Breier A, McGlashan TH. Neuropsychological status of subjects at high risk for a first episode of psychosis. Schizophrenia Research 2004, 67: 115-122. PMID: 14984870, DOI: 10.1016/j.schres.2003.08.007.Peer-Reviewed Original ResearchConceptsFirst episodeFirst psychotic episodeLevel of impairmentSchizophrenia prodromePsychotic episodeHigh riskMulti-site studyProdromal interventionPopulation normsNeuropsychological examNeuropsychological StatusNeuropsychological functioningNormal intelligenceEpisodesSchizophrenia samplePsychosisSubjectsRiskStatusProdromeSchizophreniaImpairmentSeverity
2003
Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome
Woods SW, Breier A, Zipursky RB, Perkins DO, Addington J, Miller TJ, Hawkins KA, Marquez E, Lindborg SR, Tohen M, McGlashan TH. Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biological Psychiatry 2003, 54: 453-464. PMID: 12915290, DOI: 10.1016/s0006-3223(03)00321-4.Peer-Reviewed Original ResearchConceptsExtrapyramidal symptomsPlacebo-controlled trialShort-term efficacyTrial of olanzapineTreatment x time interactionGreater symptomatic improvementSymptom total scoreX time interactionGreater weight gainRepeated-measures analysisOlanzapine patientsSchizophrenic prodromeOlanzapine treatmentPlacebo patientsSymptomatic improvementAcute treatmentMore patientsOlanzapine 5Prodromal symptomsRoutine treatmentProdromal patientsProdromal phaseWeek 8Week 6PlaceboThe PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis II. Baseline characteristics of the “prodromal” sample
Miller TJ, Zipursky RB, Perkins D, Addington J, Woods SW, Hawkins KA, Hoffman R, Preda A, Epstein I, Addington D, Lindborg S, Marquez E, Tohen M, Breier A, McGlashan TH. The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis II. Baseline characteristics of the “prodromal” sample. Schizophrenia Research 2003, 61: 19-30. PMID: 12648732, DOI: 10.1016/s0920-9964(02)00440-1.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntipsychotic AgentsBenzodiazepinesBipolar DisorderComorbidityDepressive Disorder, MajorDouble-Blind MethodFemaleHumansMaleMood DisordersOlanzapinePirenzepinePsychomotor DisordersPsychotic DisordersRisk FactorsSchizophreniaSchizophrenic PsychologySleep Wake DisordersSpeech DisordersConceptsFirst-episode schizophreniaEpisode schizophreniaTreatment-seeking patientsClinical trialsDouble-blind placebo-controlled clinical trialProdromal SyndromesDouble-blind clinical trialPlacebo-controlled clinical trialAtypical neuroleptic medicationsMild affective symptomsNew diagnostic criteriaSerious mental illnessClinical trial samplesUntreated first-episode schizophreniaSubstance use/abuseEffects of drugsPutative prodromal syndromeUse/abuseUnusual thought contentAdolescent maniaOngoing symptomatologyProdromal sampleStudy medicationBaseline characteristicsMost patientsThe PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis I. Study rationale and design
McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller TJ, Woods SW, Hawkins KA, Hoffman R, Lindborg S, Tohen M, Breier A. The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis I. Study rationale and design. Schizophrenia Research 2003, 61: 7-18. PMID: 12648731, DOI: 10.1016/s0920-9964(02)00439-5.Peer-Reviewed Original ResearchConceptsPsychosis onsetClinical trialsDouble-blind placebo-controlled clinical trialStudy rationaleDouble-blind clinical trialPlacebo-controlled clinical trialAtypical neuroleptic medicationsNew diagnostic criteriaClinical trial designPutative prodromal syndromeTreatment-seeking patientsOngoing symptomatologyNeuroleptic medicationHigh riskDiagnostic criteriaTrial designEarly courseProdromal SyndromesClinical phenomenologyStudy designClinical populationsPatientsOnsetIntervention researchTrials